Author:
Piña Ileana L.,Targum Shari L.
Reference21 articles.
1. Cohn, JN. Inotropic therapy for heart failure: paradise postponed. N. Engl. J. Med. 1989;320(11):729–31.
2. O’Connor, CM, et al. Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). J. Am. Coll. Cardiol. 2003;41(9):1452–57.
3. Massie, BM, et al. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET). Circulation 1993;88(2):492–501.
4. Packer, M. PROFILE abstract. Circulation 88(suppl I), I-301 (1993).
5. Center for Drug Evaluation and Research Advisory Committee: Cardiovascular and Renal Drugs Advisory Committee. Evaluation of Long-term Treatment with Cyclic AMP Dependent Positive Inotropic Agents. Food and Drug Administration. January 27, 1998.